167 related articles for article (PubMed ID: 30635085)
1. Computational and modeling approaches to understand the impact of the Fabry's disease causing mutation (D92Y) on the interaction with pharmacological chaperone 1-deoxygalactonojirimycin (DGJ).
Thirumal Kumar D; Judith E; Priyadharshini Christy J; Siva R; Tayubi IA; Chakraborty C; George Priya Doss C; Zayed H
Adv Protein Chem Struct Biol; 2019; 114():341-407. PubMed ID: 30635085
[TBL] [Abstract][Full Text] [Related]
2. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.
Benjamin ER; Flanagan JJ; Schilling A; Chang HH; Agarwal L; Katz E; Wu X; Pine C; Wustman B; Desnick RJ; Lockhart DJ; Valenzano KJ
J Inherit Metab Dis; 2009 Jun; 32(3):424-40. PubMed ID: 19387866
[TBL] [Abstract][Full Text] [Related]
3. α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.
Siekierska A; De Baets G; Reumers J; Gallardo R; Rudyak S; Broersen K; Couceiro J; Van Durme J; Schymkowitz J; Rousseau F
J Biol Chem; 2012 Aug; 287(34):28386-97. PubMed ID: 22773828
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants.
Yam GH; Bosshard N; Zuber C; Steinmann B; Roth J
Am J Physiol Cell Physiol; 2006 Apr; 290(4):C1076-82. PubMed ID: 16531566
[TBL] [Abstract][Full Text] [Related]
5. Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease.
Park JY; Kim GH; Kim SS; Ko JM; Lee JJ; Yoo HW
Exp Mol Med; 2009 Jan; 41(1):1-7. PubMed ID: 19287194
[TBL] [Abstract][Full Text] [Related]
6. Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo) causative mutations and two amenable variants to the chaperone DGJ.
Ferri L; Malesci D; Fioravanti A; Bagordo G; Filippini A; Ficcadenti A; Manna R; Antuzzi D; Verrecchia E; Donati I; Mignani R; Cavicchi C; Guerrini R; Morrone A
Clin Chim Acta; 2018 Jun; 481():25-33. PubMed ID: 29476735
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants.
Yu Y; Mena-Barragán T; Higaki K; Johnson JL; Drury JE; Lieberman RL; Nakasone N; Ninomiya H; Tsukimura T; Sakuraba H; Suzuki Y; Nanba E; Mellet CO; García Fernández JM; Ohno K
ACS Chem Biol; 2014 Jul; 9(7):1460-9. PubMed ID: 24783948
[TBL] [Abstract][Full Text] [Related]
8. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.
Ishii S; Chang HH; Kawasaki K; Yasuda K; Wu HL; Garman SC; Fan JQ
Biochem J; 2007 Sep; 406(2):285-95. PubMed ID: 17555407
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease.
Lukas J; Cimmaruta C; Liguori L; Pantoom S; Iwanov K; Petters J; Hund C; Bunschkowski M; Hermann A; Cubellis MV; Rolfs A
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023956
[TBL] [Abstract][Full Text] [Related]
10. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease.
Khanna R; Soska R; Lun Y; Feng J; Frascella M; Young B; Brignol N; Pellegrino L; Sitaraman SA; Desnick RJ; Benjamin ER; Lockhart DJ; Valenzano KJ
Mol Ther; 2010 Jan; 18(1):23-33. PubMed ID: 19773742
[TBL] [Abstract][Full Text] [Related]
11. Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease.
Sugawara K; Tajima Y; Kawashima I; Tsukimura T; Saito S; Ohno K; Iwamoto K; Kobayashi T; Itoh K; Sakuraba H
Mol Genet Metab; 2009 Apr; 96(4):233-8. PubMed ID: 19181556
[TBL] [Abstract][Full Text] [Related]
12. Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone.
Shin SH; Kluepfel-Stahl S; Cooney AM; Kaneski CR; Quirk JM; Schiffmann R; Brady RO; Murray GJ
Pharmacogenet Genomics; 2008 Sep; 18(9):773-80. PubMed ID: 18698230
[TBL] [Abstract][Full Text] [Related]
13. Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease.
Ishii S; Chang HH; Yoshioka H; Shimada T; Mannen K; Higuchi Y; Taguchi A; Fan JQ
J Pharmacol Exp Ther; 2009 Mar; 328(3):723-31. PubMed ID: 19106170
[TBL] [Abstract][Full Text] [Related]
14. Functional Characterization and Pharmacological Evaluation of a Novel GLA Missense Mutation Found in a Severely Affected Fabry Disease Family.
Varela P; Mastroianni Kirsztajn G; Ferrer H; Aranda C; Wallbach K; Ferreira da Mata G; Moura LA; Moreira SR; Mendes C; Curiati MA; Martins AM; Bosco Pesquero J
Nephron; 2020; 144(3):147-155. PubMed ID: 31665721
[TBL] [Abstract][Full Text] [Related]
15. Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests.
Andreotti G; Citro V; De Crescenzo A; Orlando P; Cammisa M; Correra A; Cubellis MV
Orphanet J Rare Dis; 2011 Oct; 6():66. PubMed ID: 22004918
[TBL] [Abstract][Full Text] [Related]
16. The molecular basis of pharmacological chaperoning in human α-galactosidase.
Guce AI; Clark NE; Rogich JJ; Garman SC
Chem Biol; 2011 Dec; 18(12):1521-6. PubMed ID: 22195554
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
[TBL] [Abstract][Full Text] [Related]
18. DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts.
Fantur K; Hofer D; Schitter G; Steiner AJ; Pabst BM; Wrodnigg TM; Stütz AE; Paschke E
Mol Genet Metab; 2010 Jul; 100(3):262-8. PubMed ID: 20409738
[TBL] [Abstract][Full Text] [Related]
19. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.
Takai T; Higaki K; Aguilar-Moncayo M; Mena-Barragán T; Hirano Y; Yura K; Yu L; Ninomiya H; García-Moreno MI; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
Mol Ther; 2013 Mar; 21(3):526-32. PubMed ID: 23337983
[TBL] [Abstract][Full Text] [Related]
20. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease.
Lukas J; Giese AK; Markoff A; Grittner U; Kolodny E; Mascher H; Lackner KJ; Meyer W; Wree P; Saviouk V; Rolfs A
PLoS Genet; 2013; 9(8):e1003632. PubMed ID: 23935525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]